Changes in serum lipid and (APO) lipoprotein levels in renal transplant recipients

A long‐term study on hyperlipidemia in stable renal transplant recipients

“…A series from Taiwan reported prevalence rates of 7.7, 34, 31.6 and 40.0% at baseline, 1, 2, and 3 yr, respectively for hypercholesterolemia (TC > 6.4 mmol/L) (20), but details on the allograft function and lipid lowering treatment were not given. In another series from Thailand, 55% of (16). Taken together, these results suggest significant regional variation in the severity and/or pattern of hyperlipidemia after kidney transplantation.…”

“…Data from cross‐sectional and longitudinal studies on post‐transplant lipid disturbances has demonstrated that hyperlipidemia affected up to 60% of renal allograft recipients within the first few years, and that treatment with corticosteroid and cyclosporine are important contributing factors (12–21). Ong et al presented longitudinal data on 192 patients followed up for 250 months, and showed that total cholesterol first peaked at 3 months post‐transplant, then decreased, followed by another increase after 10 yr (19).…”

“…Nevertheless, we observed a lower proportion (34.2%) of patients having risk ratios exceeding 4.5 at the corresponding time‐point. A series from Japan reported that 17 of 36 non‐diabetic patients transplanted for 51.3 months were hypercholesterolemic (TC > 6.68 mmol/L), with the commonest lipoprotein phenotype being type IV and type IIa, although again details on treatment were not mentioned (16). Taken together, these results suggest significant regional variation in the severity and/or pattern of hyperlipidemia after kidney transplantation.…”

“…It is important to note that, despite the decreasing incidence of hypercholesterolemia with increasing duration after transplantation, the incidence of patients having a high risk-ratio actually remained similar at 5-10% per year throughout the first 3 yr, so that despite statin therapy in about one-fifth of patients 19.0% of patients had elevated LDL and 21.8% of patients had abnormal risk-ratios at the end of the third year. Data from cross-sectional and longitudinal studies on post-transplant lipid disturbances has demonstrated that hyperlipidemia affected up to 60% of renal allograft recipients within the first few years, and that treatment with corticosteroid and cyclosporine are important contributing factors (12)(13)(14)(15)(16)(17)(18)(19)(20)(21). Ong et al presented longitudinal data on 192 patients followed up for 250 months, and showed that total cholesterol first peaked at 3 months post-transplant, then decreased, followed by another increase after 10 yr (19).…”